Jonathan Frampton

Vice President Of Business Development at ProteoNic

Jonathan Frampton is an experienced business development professional specializing in bioproduction and biotechnology sectors. Currently serving as Vice President of Business Development at ProteoNic since May 2023, Jonathan focuses on enhancing cost-efficiency and scalability through innovative vector technology for therapeutic proteins and viral vectors. With a robust background that includes roles such as Director at JMF Biotech Consulting and Head of Business Development at Qkine, Jonathan has extensive expertise in commercial growth strategies, coaching, and market development. Previous roles include Chief Commercial Officer at Metisox, Corporate Development Partner and Key Account Partner at Horizon Discovery, and various positions at Diagenode and Abcam. Jonathan holds a PhD in Biochemistry and a BSc in Biology from the University of Sussex.

Location

Cambridge, United Kingdom

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


ProteoNic

ProteoNic is a biotechnology company active in development and licensing of DNA technology for cell line generation and recombinant protein production for pharmaceutical applications. We offer premium vector technology that substantially boosts production levels of therapeutic proteins and other biologics. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins. ProteoNic’s 2G UNic™ drives higher production for all types of therapeutic protein products, including monoclonal antibodies, biosimilars and more difficult-to-express (DTE) proteins, such as Fc-fusion proteins and bi-specifics, contributing to their economic viability. Our patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Independent technical and commercial validation by third parties, including top tier biopharma, demonstrates severalfold productivity level increases that translate into multi-million Euros in annual cost savings. The technology has wide ranging potential to boost production efficiencies in other important applications, including viral vector production, protein production in yeast and technologies which impact product quality. The company is headquartered at the BioScience Park in Leiden, the Netherlands and has a Boston, USA office for Business Development in the North American market.


Employees

11-50

Links